Jiuzhou pharmaceutical co., ltd (603456. SH): The license obtained is non-exclusive and limited to the raw materials of nematevir generic drugs-

Zhitong Finance APP News, Jiuzhou Pharmaceutical (603456. SH) Announcement: Recently, MPP ("Pharmaceutical Patent Pool Organization") issued an announcement and related media reports, and MPP authorized 35 pharmaceutical companies, including Jiuzhou Pharmaceutical Co., Ltd., to produce generic drugs of the oral drug paciclovir in COVID-19.

According to Pfizer -MPP agreement, MPP granted the company a non-exclusive license to use relevant patents and know-how to produce generic raw materials of COVID-19 oral drugs Nimatreville (Nimatvir and Ritonavir) under study, and to commercialize cooperative drugs and related rights in this region (95 low-and middle-income countries or public procurement institutions such as India, Indonesia and Egypt). Before the commercial production of the cooperative drugs under this license, it is still necessary to complete the relevant technical handover, and the production facilities must be approved by SRA or certified by WHOPQ.

According to the announcement, the production and sale of cooperative drugs under this license must be approved by the relevant competent authorities (including but not limited to marketing approval) before implementation. The sales of cooperative drugs under this license after listing in this region are affected by many factors, such as (including but not limited to) the development of COVID-19 epidemic situation, production and supply chain capabilities, market competition environment, sales channels, etc., and there are uncertainties. As of the date of this announcement, the company has no cooperative drug orders. Since this license aims to help 95 low-and middle-income countries obtain cooperative drugs in an affordable way, the related pricing is expected to be lower than the company's selling price in other high-and middle-income countries.

In addition, public information shows that as of the date of this announcement, paciclovir has successively obtained (mainly including) emergency use authorization (EUA) from the US Food and Drug Administration (FDA), conditional approval from the European Medicines Agency (EMA), emergency exception approval from the Japanese Ministry of Health, Labor and Welfare, and emergency conditional approval from the National Medical Supplies Administration of China. As of the date of this announcement, the clinical data of PAXLOVID is still limited, and there may be unreported serious adverse events or unexpected adverse events when using PAXLOVID.